FOLD (Amicus Therapeutics) 1-Year Sharpe Ratio : -1.38 (As of Jun. 29, 2025)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-06-29), Amicus Therapeutics's 1-Year Sharpe Ratio is -1.38.

Competitive Comparison of Amicus Therapeutics's 1-Year Sharpe Ratio

For the Biotechnology subindustry, Amicus Therapeutics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's 1-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

Amicus Therapeutics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Amicus Therapeutics (NAS:FOLD) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Amicus Therapeutics 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » 1-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

0HF9:UK AM6:Germany

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Executives

Bradley L Campbell	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
John F Crowley	director, officer: Executive Chairman	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark	officer: Chief People Officer	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg	officer: General Counsel & Corp. Secy	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Samantha Prout	officer: Principal Accounting Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jeff Castelli	officer: VP, Program Management	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r.	officer: Chief Financial Officer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab	director	1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi	officer: Chief Financial Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Burke W Whitman	director	13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do	officer: Sr Vice President Discovery	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly	director	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth	officer: Chief Medical Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512